|
🦁
|
Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
7 auth.
Gayathri Perera,
Madelaine B. Rañola,
D. Rowe,
G. Halliday,
G. Halliday,
Nicolas Dzamko,
...
Nicolas Dzamko
|
6 |
2016 |
6
🦁
|
|
🐜
|
Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
19 auth.
Ye Zhao,
Ye Zhao,
Ye Zhao,
Gayathri Perera,
Gayathri Perera,
J. Takahashi‐Fujigasaki,
D. Mash,
J. Vonsattel,
A. Uchino,
K. Hasegawa,
...
R. J. Nichols,
J. Holton,
S. Murayama,
Nicolas Dzamko,
Nicolas Dzamko,
Nicolas Dzamko,
Glenda M. Halliday,
Glenda M. Halliday,
Glenda M. Halliday
|
5 |
2017 |
5
🐜
|
|
🐜
|
Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
19 auth.
Ye Zhao,
Ye Zhao,
Ye Zhao,
Gayathri Perera,
Gayathri Perera,
J. Takahashi‐Fujigasaki,
D. Mash,
J. Vonsattel,
A. Uchino,
K. Hasegawa,
...
R. J. Nichols,
J. Holton,
S. Murayama,
Nicolas Dzamko,
Nicolas Dzamko,
Nicolas Dzamko,
Glenda M. Halliday,
Glenda M. Halliday,
Glenda M. Halliday
|
5 |
2017 |
5
🐜
|
